Compare DexCom, Inc. (DXCM) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.92, up 0.95% on the day, with a technical outlook leaning bearish based on moving averages while oscillators are neutral. The ETF recently executed a 1:10 forward stock split effective May 18, 2026, which adjusts share count without altering the fund's net asset value. Recent financial news highlights platinum's underperformance relative to gold and silver, suggesting potential for a catch-up trade.

The outlook for PPLT hinges on platinum's price dynamics and investor appetite for precious metals diversification. Key opportunities include its role as a pure-play physical platinum vehicle amid potential commodity rallies, but risks involve commodity price volatility, lack of dividends, and sensitivity to industrial demand and macroeconomic factors.